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Background: Both systemic inflammatory reaction and regional myocardial ischemia/reperfusion injury may 
elicit hypercoagulability after off-pump coronary artery bypass grafting (OPCAB). We investigated the influence 
of ulinastatin, which suppresses the activity of polymorphonuclear leukocyte elastase and production of pro-
inflammatory cytokines, on coagulation in patients with elevated high-sensitivity C-reactive protein (hsCRP) 
undergoing OPCAB.
Methods: Fifty patients whose preoperative hsCRP > 3.0 mg/L were randomly allocated into the ulinastatin (600,000 
U) or control group. Serum concentrations of thrombin-antithrombin complex (TAT) and prothrombin fragment 1+2 
(F1+2) were measured preoperatively, immediately after surgery, and at 24 h after surgery, respectively. Secondary 
endpoints included platelet factor (PF)-4, amount of blood loss, and transfusion requirement.
Results: All baseline values of TAT, F1+2, and PF-4 were higher than the normal range in both groups. F1+2 was 
elevated in both groups at immediate, and at 24 h after surgery as compared to baseline value, without any significant 
intergroup differences. Remaining coagulation parameters, transfusion requirement and blood loss during operation 
and postoperative 24 h were not different between the two groups.
Conclusions: Intraoperative administration of ulinastatin did not convey beneficial influence in terms of coagulation 
and blood loss in high-risk patients with elevated hsCRP undergoing multivessel OPCAB, who already exhibited 
hypercoagulability before surgery. (Korean J Anesthesiol 2013; 64: 105-111)
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Introduction
Despite avoiding cardiopulmonary bypass (CPB) and 
global myocardial ischemia, a considerable degree of systemic 
inflammatory reaction still develops during off-pump coronary 
artery bypass grafting (OPCAB) [1]. In addition, various degree 
of cumulative regional warm ischemia/reperfusion (I/R) injury 
occurs following multivessel grafting. Of concern, regional 
warm I/R injury predisposed patients to increased thrombin 
formation and hypercoagulable state in previous studies, which 
may be aggravated by the accompanying systemic inflamma-
tory response [2]. In OPCAB, hypercoagulable state during the 
perioperative period may draw particular attention in terms 
of decreased graft patency and development of major adverse 
cardiac events (MACE) as compared to conventional on-pump 
coronary artery bypass grafting (CABG) [3].
Ulinastatin is a glycoprotein extracted and purified from 
human urine. It suppresses the activity of polymorphonuclear 
leukocyte elastase (PMNE) [4], and has been reported to 
decrease systemic inflammatory response following CPB [5]. 
Furthermore, in view of coagulation, it inhibited coagulation and 
fibrinolysis following major abdominal surgery [6]. 
Under recognition of the central role of inflammation in coro-
nary artery occlusive disease (CAOD), high sensitivity C-reactive 
protein (hsCRP), an acute phase reactant in inflammation, has 
been regarded as an important predictor of poor postoperative 
outcome as well as cardiovascular risk in CAOD patients [7,8]. 
Inflammation contributes to the thrombotic response and 
influences the initiation and propagation of blood coagulation 
[9], and CRP was reported to directly influence thrombin 
generation and/or coagulation activation [10]. Therefore, 
patients with elevated preoperative hsCRP undergoing OPCAB 
may be more prone to develop a hypercoagulable state during 
the perioperative period, while studies validating the efficacy 
for preventive measures in this subset of patients are lacking.
In the present study, we designed this prospective single-site, 
double-blinded, randomized, and controlled trial to investigate 
the effect of ulinastatin on coagulation system, especially 
regarding the markers of thrombin formation, in patients with 
elevated preoperative hsCRP undergoing multivessel OPCAB.
Materials and Methods
After obtaining approval from our Institutional Review Board 
and written informed consent from the patients, 50 patients 
scheduled for elective OPCAB were enrolled for the present 
study. The inclusion criteria were patients in whom preoperative 
hsCRP measured one day before the operation was greater than 
3.0 mg/L [7]. Patients were excluded in case of salvage and/
or emergency operation, preoperative serum creatinine > 1.4 
mg/dl, liver disease, preoperative heparinization or preexisting 
coagulation disorder. Patients who met the inclusion criteria 
were randomized into the ulinastatin or control group accor-
ding to computer-generated codes. The group assignment for 
each patient was sealed in sequentially numbered, opaque 
envelopes. A nurse who was not involved in the anesthesia and 
postoperative care of the patients opened these envelopes and 
prepared ulinastatin or saline solution according to the group 
assignment to ensure double-blindness.
Primary end point of the current study was to serially com-
pare serum concentrations of thrombin-antithrombin complex 
(TAT) and prothrombin fragment 1+2 (F1+2) between the 
groups, which are well-known indices of in vivo thrombin 
generation [11]. Secondary end points of this study were to 
compare differences in other coagulation parameters including 
platelet factor (PF)-4, amount of postoperative blood loss, and 
the incidence of postoperative myocardial infarction (MI).
Patients were premedicated with 0.05-0.1 mg/kg of intra-
muscular morphine 1 h before the operation. Standard moni-
toring devices were applied to the patients on arrival at the 
operating room, including 5-lead electrocardiogram, pulse 
oximetry, a radial artery catheter and a pulmonary artery 
catheter (PAC, Swan-Ganz Combo CCO/SvO2, Edwards 
Lifesciences LLC, USA). PAC was inserted through the right 
internal jugular vein and connected to an analysis system 
(Vigilance, Edwards Lifesciences LLC, USA) for continuous 
monitoring of the cardiac index and mixed venous oxygen 
saturation (SvO2). Anesthesia was induced with intravenous 
midazolam (0.03-0.07 mg/kg), sufentanil (1.5-2.0 μg/kg) and 
rocuronium (0.9 mg/kg). Patients’ lungs were mechanically 
ventilated with a tidal volume of 7-8 mg/kg and a positive end-
expiratory pressure of 5 cmH2O at a rate of 8-12 breaths/min 
to maintain normocarbia. Anesthesia was maintained with 
0.8-1.5% of sevoflurane in a 40% oxygen/air mixture and a 
continuous infusion of sufentanil (0.5-1.5 μg/kg/h).
In the ulinastatin group, 300,000 U of intravenous ulinastatin 
was administered after anesthetic induction and at the onset 
of Y-graft construction, respectively. In the control group, 
equal volume of saline placebo was administered at each 
corresponding time points.
After a median sternotomy, the heart was displaced using 
posterior pericardial stitches, large gauze swabs and tissue 
stabilizer (Octopus, Medtronic Inc., USA). During the period 
of heart displacement, crystalloid solution was infused at a 
fixed rate of 6 ml/kg/h, and colloid solution was administered 
according to the estimated blood loss. The blood salvaged by the 
cell salvage device was re-infused to the patient after sternum 
closure. During the period of heart displacement and grafting, 
hypotension (mean systemic arterial pressure below 70 mmHg) 
was managed using either a 5-10o Trendelenburg position 
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or a norepinephrine infusion. Intravenous milrinone was 
infused at 0.5 μg/kg/min if a SvO2 < 60% for more than 10 min 
or mitral regurgitation ≥ grade 3 developed with a concomitant 
increase in the mean pulmonary arterial pressure > 30 mmHg. 
Allogeneic packed red blood cells (pRBCs) were transfused to 
maintain the hematocrit (Hct) > 25% for patients aged more 
than 65 years and > 22% for patients aged less than 65 years 
throughout the study period. The blood temperature measured 
by a PAC was maintained above 36oC with a warm mattress, a 
forced warm air blanket and a fluid warmer as necessary.
For intraoperative anticoagulation, intravenous heparin 
(100 U/kg) was administered at the completion of left internal 
mammary artery harvesting. Activated clotting time (ACT) was 
measured 5 min after the initial administration of heparin and 
repeated at an interval of 30 min thereafter until the completion 
of grafting. Additional 2,000 U of heparin was administered if 
the ACT was less than 250 s. Anticoagulation was reversed with 
0.5 mg of protamine per 100 U of heparin.
All the patients were transferred to the intensive care unit 
(ICU) after the surgery. The ICU staffs who were not aware 
of the study groups conducted the postoperative care of the 
patients, including decisions for hemodynamic management, 
transfusion, extubation and discharge from the ICU according 
to the standard ICU protocols of our institution. Postoperative 
antiplatelet therapy comprising of 100 mg of aspirin and 75 
mg of PO clopidogrel once a day, was started from the evening 
of the surgery, unless contraindicated. None of the patients 
received postoperative heparinization during the study period. 
Blood samples for the measurements of TAT, F1+2, PF-
4, prothrombin time (PT), activated partial thromboplastin 
time (aPTT), hsCRP, white blood cell (WBC) count, neutrophil 
count, hematocrit, platelet count, creatine kinase (CK)-MB, and 
troponin (Tn)-T were obtained preoperatively, immediately 
after surgery, and 24 h after surgery. Fluid balance, amount 
of blood loss, and transfusion requirement during operation 
and postoperative 24 h were also recorded. Postoperative MI 
was defined as the occurrence of an increase in Tn-T or CK-
MB more than 5 times the upper normal limit when associated 
with the development of new pathologic Q-wave or left bundle 
branch block on the electrocardiogram.
Based on a previous study [6], 22 patients were required in 
each group for 90% power to detect a 20 ng/ml difference in the 
TAT between the groups with a SD of 20 ng/ml at an α value of 
0.05. The study size was set as 25 patients in each group consi-
dering a dropout rate of 10%. All data are expressed as mean ± 
SD or median (IQR) or the number of patients. The data were 
analyzed using χ2 tests, Fisher’s exact test, independent t-tests 
or Wilcoxon signed rank tests as appropriate. The repeatedly 
obtained data were analyzed by repeated measures of ANOVA 
or Friedman tests according to the normality of distribution. 
Post-hoc tests were conducted with Bonferroni correction. The 
statistical analyses were performed using SAS 9.1.3 (Institute 
Inc., Cary, NC, USA). A P value of less than 0.05 was considered 
statistically significant.
Results
OPCAB was successfully performed in all 50 patients. Pre-
operative characteristics of the patients were similar between 
the two groups (Table 1).
Coagulation parameters including TAT, F1+2, and PF-4 
are shown in Table 2. There were no differences in TAT, F1+2, 
PF-4 PT, and aPTT between the groups throughout the study 
period. Baseline values of TAT, F1+2, and PF-4 were all above 
the normal reference range in both groups. F1+2 increased 
immediately after surgery (P = .005 and P < .001 for the 
control and ulinastatin group, respectively) and 24 h after 
surgery (P = .031 and P < .001 for the control and ulinastatin 
group, respectively) in both groups as compared to individual 
corresponding baseline value. No change in the values of 
TAT and PF-4 was observed throughout the study period as 
compared to each corresponding baseline value. 
There were no significant differences in hematologic 
parameters, hsCRP, and cardiac enzymes between the groups 
throughout the study period (Table 3). A decrease in HsCRP was 
observed immediately after surgery (P < .05) and an increase 
was noted at 24 h after surgery without any difference between 
Table 1. Patients’ Characteristics
Control  
(n = 25)
Ulinastatin  
(n = 25)
Sex (M/F)
Age (yr)
Height (cm)
Weight (kg)
EF (%)
EuroSCORE
Diabetes mellitus
Hypertension
Preoperative medication
    Statin
    Aspirin
    Clopidogrel
    Beta blocker
    Calcium channel blocker
    ACE inhibitor
    Aspirin discontinuation (days)
    Clopidogrel discontinuation (days)
Antithrombin III (%)
Fibrinogen (mg/dl)
17/8
63 ± 9
160 ± 7
62 ± 8
55 ± 19
4.5 (2-6)
11 (46%)
15 (60%)
18 (72%)
20 (80%)
15 (60%)
11 (44%)
13 (52%)
7 (28%)
1.9 ± 1.5
2.2 ± 1.7
91.1 ± 13.6
415 ± 94
19/6
67 ± 10
165 ± 10
66 ± 11
60 ± 13
3 (1-5)
16 (64%)
20 (83%)
18 (72%)
15 (63%)
12 (48%)
15 (63%)
14 (58%)
9 (36%)
2.2 ± 1.5
2.7 ± 1.7
88.8 ± 16.7
418 ± 98
Values are mean ± standard deviation or median (interquartile range) 
or number of patients (percentage). EF: left ventricular ejection 
fraction, ACE inhibitor: angiotensin converting enzyme inhibitor. 
There were no significant differences between the two groups.
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the groups (P < .001, Table 3). 
There were no differences in parameters of intraoperative 
anticoagulation including initial ACT, amount of heparin 
injected, mean, minimum and maximum ACT during the 
operation, amount of protamine for heparin reversal and final 
ACT between the groups (Table 4).
Fluid balance and amount of blood loss during the operation 
and postoperative 24 h were similar between the groups. 
Requirement for pRBC transfusion during the operation and 
postoperative 24 h were also similar between the groups (Table 5). 
10 patients in control group and 7 patients in ulinastatin group 
were transfused respectively and all the patients who were 
Table 2. Parameters Related to Coagulation
Preoperative Immediate after surgery 24 h after surgery
TAT (ng/ml) Control
     Ulinastatin
F1+2 (nmol/L) Control
 Ulinastatin
PF-4 (IU/ml) Control
 Ulinastatin
PT (s) Control
 Ulinastatin
aPTT (s) Control
 Ulinastatin
30.3 (23.1-49.9)
26.0 (18.1-44.3)
1.06 (0.58-1.84)
1.09 (0.55-3.53)
19.2 ± 1.4
19.0 ± 1.3
11.2 ± 0.6
10.9 ± 0.8
32.9 ± 9.6
33.1 ± 10.9
27.6 (13.5-53.0)
38.7 (18.5-51.1)
2.54 (1.02-4.15)*
4.54 (1.73-6.90)*
18.8 ± 2.2
19.2 ± 1.0
12.8 ± 1.2*
12.7 ± 1.2*
31.3 ± 4.8
30.2 ± 5.3
29.1 (17.2-41.8)
30.4 (18.4-43.8)
3.29 (1.05-6.49)*
3.75 (1.12-7.36)*
18.7 ± 1.7
18.3 ± 2.5
12.7 ± 1.0*
12.6 ± 1.0*
31.2 ± 8.5
30.5 ± 5.0
Values are mean ± standard deviation or median (interquartile range). TAT: thrombin-antithrombin complex, F1+2: prothrombin fragment 1+2, 
PF-4: platelet factor-4, PT: prothrombin time, aPTT: activated partial thromboplastin time. *P < 0.05 vs preoperative value.
Table 3. Hematologic Parameters, hsCRP and Cardiac Enzymes
Control Ulinastatin
hsCRP (mg/L)
    Preoperative
    Immediate after surgery
    24 h after surgery
WBC (/mm3)
    Preoperative
    Immediate after surgery
    24 h after surgery
Neutrophil (%)
    Preoperative
    Immediate after surgery
    24 h after surgery
Hematocrit (%)
    Preoperative
    Immediate after surgery
    24 h after surgery
Platelet (103/mm3)
    Preoperative
    Immediate after surgery
    24 h after surgery
CK-MB (ng/ml)
    Preoperative
    Immediate after surgery
    24 h after surgery
Tn-T (ng/ml)
    Preoperative
    Immediate after surgery
    24 h after surgery
7.6 (4.0-27.9)
6.1 (2.6-13.5)*
89.7 (70.2-119.0)*
7,383 ± 1,731
10,209 ± 2,780*
12,859 ± 3,145*
59 ± 10
80 ± 9*
85 ± 8*
37 ± 7
28 ± 3*
27 ± 5*
230 ± 92
173 ± 66*
173 ± 68*
2.0 (1.5-2.5)
4.3 (3.7-4.9)*
8.3 (5.2-13.6)*
0.013 (0.010-0.093)
0.087 (0.040-0.133)*
0.147 (0.078-0.246)*
11.2 (4.5-15.8)
5.2 (2.5-9.7)*
97.7 (78.1-125.0)*
7,706 ± 1,918
10,966 ± 2,813*
13,320 ± 3,220*
60 ± 11
82 ± 6*
85 ± 5*
37 ± 5
28 ± 3*
28 ± 3*
248 ± 50
176 ± 55*
186 ± 46*
2.2 (1.6-2.9)
4.0 (3.6-6.4)*
5.5 (4.5-7.9)*
0.010 (0.010-0.152)
0.111 (0.061-0.210)*
0.159 (0.079-0.245)*
Values are mean ± standard deviation or median (interquartile range). 
hsCRP: high sensitivity C-reactive protein, WBC: white blood cell, CK-
MB: creatine kinase-MB, Tn-T: Troponin-T. *P < 0.05 vspreoperative 
value.
Table 4. Parameters of Intraoperative Anticoagulation
Control 
(n = 25)
Ulinastatin 
(n = 25)
Initial ACT (s)
Dose of heparin (U)
Mean ACT during grafting (s)
Minimum ACT during grafting (s)
Maximum ACT during grafting (s)
Dose of protamine (mg)
Final ACT (s)
141 ± 15
6,714 ± 1,443
290 ± 58
242 ± 42
342 ± 91
33 ± 12
156 ± 15
148 ± 17
6,414 ± 1,489
277 ± 41
241 ± 40
329 ± 66
28 ± 11
152 ± 24
Values are mean ± standard deviation. ACT: activated clotting time. 
There were no significant differences between the two groups.
Table 5. Amount of Blood Loss, Fluid Balance and Transfusion 
Requi re ment during the Operation and Postoperative 24 h
Control 
(n = 25)
Ulinastatin 
(n = 25)
Intraoperative 
    Crystalloid (ml)
    Colloid (ml)
    Urine output (ml)
    Blood loss (ml)
    pRBC transfusion (unit)
    Number of patients who required pRBC
Postoperative 24 h 
    Crystalloid (ml)
    Colloid (ml)
    Urine output (ml)
    Blood loss (ml)
    pRBC transfusion (unit)
    Number of patients who required pRBC
2,050 ± 619
1,037 ± 277
461 ± 443
286 ± 183
0 (0-2)
10 (40%)
3,904 ± 741
353 ± 244
2,991 ± 760
632 ± 206
0 (0-2)
4 (16%)
2,224 ± 390
1,062 ± 286
557 ± 381
285 ± 202
0 (0-2)
7 (28%)
3,592 ± 1,059
280 ± 310
2,953 ± 675
571 ± 160
0 (0-1)
2 (8%)
Values are mean ± standard deviation or median (range) or number 
of patients (percentage). pRBC: packed red blood cell. There were no 
significant differences between the two groups.
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transfused were over 65 years old except one patient in control 
group. 
There were no differences in the duration of ICU stay (3 [3-
4] days vs. 3 [3-4] days for the control and ulinastatin group, 
respectively, P = .206) and postoperative hospitalization (11 
[9-18] days vs. 9 [9-11] days for the control and ulinastatin 
group, respectively, P = .234) between the groups. In addition, 
the incidence of postoperative MI during hospitalization was 
not different between the two groups (0 vs. 1 in the control and 
ulinastatin group, respectively, P = 1.000). 
Discussion
In this prospective, double-blinded, randomized, and 
controlled study addressing the effect of ulinastatin on 
coagulation in patients whose preoperative hsCRP >3 mg/L 
and were undergoing multivessel OPCAB, we could not observe 
any beneficial effects of ulinastatin in terms of mitigating 
development of postoperative hypercoagulable state.
Ulinastatin, a glycoprotein extracted and purified from 
human urine, inhibits PMNE activity [4] and production of 
pro-inflammatory cytokines [12,13]. Thus, it has been used in 
the case of patients with inflammatory disorders such as pan-
creatitis, shock and disseminated intravascular coagulation [14].
Ulinastatin has also been reported to decrease systemic 
inflammatory response following CPB [5] or trauma with 
hemorrhagic shock [15]. Furthermore, in view of coagulation, 
ulinastatin has been reported to normalize the coagulation 
function during liver resection [16], and inhibit coagulation and 
fibrinolysis following major abdominal surgery [6]. 
In hemostatic mechanism, PMNE activity can influence 
coagulation by modulating various steps. Cleavage of 
thrombomodulin from the endothelial cell surface by PMNE 
generates a much less active form of thrombomodulin [17], 
which could lead to inhibition of protein C pathway and 
procoagulant state [9]. PMNE is also known to degrade 
antithrombin [18]. On the other hand, PMNE enhances 
fibrinolysis by causing degradation of cross-linked fibrin [19]. 
TNF suppresses transcription of the thrombomodulin gene 
in endothelial cells and may affect coagulation [20]. Indeed, 
ulinastatin has been reported to decrease the levels of PMNE, 
TNF-α, IL-6 and IL-8 after CPB [9]. Not surprisingly, ulinastatin 
administrated before CPB attenuated the elevation of IL-6 
and IL-8, increased stroke volume index, and decreased 
intrapulmonary shunt after CPB [21]. In view of coagulation, 
ulinastatin (6,000 U/kg) attenuated postoperative increase 
in TAT and fibrin degradation product (FDP) in abdominal 
surgery, suggesting inhibitory effect of ulinastatin on 
coagulation and fibrinolysis associated with major surgery [6]. 
However, evidence is limited regarding the effect of ulinastatin 
on coagulation during perioperative period in cardiac surgery.
In conventional on-pump surgery, a relatively low incidence 
of postoperative thrombotic events was supposed to be 
attributed in part to an unidentified anticoagulating effect of 
CPB [22]. On the contrary, OPCAB can lead to a postoperative 
hypercoagulable state by circumventing CPB [23]. In addition, 
cumulative regional warm I/R may potentially contribute to 
postoperative thrombotic complications. Inflammation also 
affects coagulation cascades in favor of thrombosis through 
cellular and humoral modulation. Inflammatory cytokines initiate 
coagulation through the induction of tissue factor expression, 
primarily on monocyte/macrophages [9]. Plasma hsCRP 
reflect chronic low-grade inflammatory conditions in patients 
without apparent inflammation, for example, diabetes mellitus, 
osteoarthritis and pulmonary disease [24]. In addition, the 
recognition of inflammatory mechanism in pathophysiology 
of atherosclerosis has drawn attention on the role of hsCRP as 
a predictor of cardiovascular events [7]. Elevated preoperative 
hsCRP has been reported to be associated with adverse 
postoperative outcome [8], and higher risk of early graft 
occlusion after CABG [25]. Furthermore, a published report 
states that CRP directly influenced thrombin generation and/
or coagulation activation in patients with stable angina [10]. 
Therefore, in patients with elevated levels of hsCRP, it may 
be reasonable to take concerns regarding the high-risk of 
developing a hypercoagulable state during the perioperative 
period, which may potentially increase the risk of ischemic 
events and endanger the patency of coronary anastomoses. In 
the current study, thus, we evaluated whether ulinastatin could 
attenuate the development of hypercoagulability in these subset 
of patients undergoing multivessel OPCAB.
In the current trial, unfortunately, we could not observe any 
significant influence of ulinastatin on postoperative TAT, F1+2 
and PF-4 levels, which are well known markers of thrombin 
and platelet activation. F1+2 is a polypeptide released from 
prothrombin during its activation to form thrombin by the 
prothrombinase complex, and subsequently thrombin is 
inhibited by the formation of TAT by antithrombin III. Thus, 
F1+2 and TAT have been generally used as indices of in vivo 
thrombin generation [11]. In this study, F1+2 measured 
immediately and 24 h after surgery were elevated from its 
preoperative value in both groups, indicating increased 
thrombin generation. Elevated levels of F1+2 after OPCAB 
has also been reported in previous studies [2,23] and could 
be a possible target for prevention of procoagulant changes 
during perioperative period. Although ulinastatin has failed to 
attenuate increased perioperative thrombin generation, there 
is a report stating that aprotinin, a serine protease inhibitor, 
could abrogate hypercoagulable state after OPCAB [3]. PF-4 
is a platelet α-granule CXC chemokine that is released during 
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platelet activation. It plays important physiologic roles in 
the processes of coagulation and excess amount of PF-4 can 
facilitate thrombosis by bringing together platelets and the 
endothelium and also by activating monocytes, which carry 
tissue factor [26]. The values of PF-4 in this study also did not 
change significantly from the preoperative value in both groups. 
Significant perioperative platelet activation does not seem to 
occur after OPCAB at least until postoperative 24 h, as shown in 
previous studies, where platelet function was evaluated using 
thromboelastography, whole blood aggregometry or platelet 
function analyzer-100 [2].
Of interesting to note in the current study is the preoperati-
vely elevated values of TAT, F1+2 and PF-4 in both group of 
patients, indicating that the patients in this study were already 
in hypercoagulable state preoperatively. It might be attributed 
to preoperative proinflammatory state as suggested by elevated 
preoperative hsCRP, and the effect of ulinastatin may not be 
sufficient enough to abrogate postoperative procoagulant 
changes in patients, who were already in hypercoagulable state 
preoperatively.
In view of the role of PMNE on coagulation and fibrinolysis 
[19], intraoperative administration of ulinastatin has been 
reported to reduce the amount of early postoperative blood loss 
in major orthopedic surgery [27], while we could not observe 
any blood conservative effect of ulinastatin in the current 
study. These differences might be associated with differences 
in the degree of PMNE activation and coagulation-fibrinolysis 
balances between the involved patients in both the studies. 
The limitations of this study are follows. Generally, intra-
operative ulinastatin was administered at doses of 5,000-6,000 
U/kg [6,21] and 1,000,000 U has been used as a maximum dose in 
cardiac surgery using CPB [5], while there is no available report, 
which states the optimal dose of ulinastatin in OPCAB. The dose 
of ulinastatin in this study (600,000 U) might not be sufficient to 
modulate coagulation function in high-risk patients undergoing 
OPCAB although the chosen dose of ulinastatin in the current 
trial was effective in terms of attenuation of proinflammatory 
response in previous studies [5,21]. In addition, we administered 
ulinastatin after induction of anesthesia and at the commence-
ment of Y-graft construction, since prothrombotic stimulation 
was supposed to be most intense during coronary anastomoses 
due to the superimposed influence of systemic inflammatory 
response and cumulative regional myocardial warm I/R injury. 
However, considering the relatively short half-life (33 min) of 
ulinastatin [28], there is a possibility that continuous infusion 
may be more favorable rather than bolus injection. Indeed, with 
bolus injection followed by continuous infusion, ulinastatin has 
been reported to decrease postoperative cardiac troponin levels 
after OPCAB [29].
Approximately 2/3 of the enrolled patients continued their 
dual antiplatelet therapy within 5 days of surgery and dual anti-
platelet therapy was resumed on the first day of surgery in all 
the patients in the current study. As recent literature suggests 
ischemic and/or mortality benefit with some degree of platelet 
inhibition in patients undergoing CABG [30], increasing 
number of patients presenting for CABG are on continued dual 
antiplatelet therapy in our daily clinical practice. Although the 
association of dual antiplatelet therapy with the development 
of hypercoagulable state remains unclear, it is hypothesized 
that it may have influenced the activation of the coagulation 
parameters. However, the proportions of patients taking aspirin 
or clopidogrel and timing of discontinuing those medications 
were not different between the control and ulinastatin groups. 
Moreover, when comparing the TAT, F1+2 and PF-4 levels in 
patients who discontinued their dual antiplatelet therapy > 5 
days of surgery, similar results were observed in their cases as 
presented (data not shown). Therefore, the influence of dual 
antiplatelet therapy should be negligible, if not, at least same in 
both groups.
In conclusion, intraoperative administration of 600,000 U 
of ulinastatin did not convey beneficial influence in terms of 
coagulation, blood loss and the incidence of MI in high-risk 
patients with elevated preoperative hsCRP values undergoing 
multivessel OPCAB.
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